Bayer: new positive data for Kerendia

(CercleFinance.com) - New data has showed positive effects of Kerendia TM (finerenone) on mortality in patients with chronic kidney disease and type 2 diabetes.


Data presented today at the European Society of Cardiology 2022 Congress highlight the potential of Kerendia TM (finerenone), compared to placebo, to significantly reduce the incidence of sudden cardiac death in a wide range of patients with chronic kidney disease (CKD) and early type 2 diabetes (T2DM).

Chronic kidney disease is a common but largely under-recognised and potentially fatal disease, potentially shortening the life expectancy of diabetic patients by up to 16 years, compared to the general population.


Copyright (c) 2022 CercleFinance.com. All rights reserved.